Loading company…
Riskpilot
← Back to search
Sign in
Get full access
BIOPHARM FORWARD ApS
APS
Active
CVR 32438784
Gammel Strandvej 442A, st. th
All other professional, scientific and technical activities n.e.c. · NACE 7499
Est. 2009
1 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2025
DKK 997K
-6% vs 2024
EBITDA margin
27.3%
-18% vs 2024
Equity ratio
77.6%
Financial strength
Net profit 2025
DKK 244K
-37% vs 2024
EBITDA — year on year
DKK millions
1M
1M
1M
0M
0M
1M
2021
0M
-100%
2022
0M
0%
2023
0M
0%
2024
0M
0%
2025
Key figures
Annual report 2025
Revenue
DKK 997K
-6%
EBITDA
DKK 272K
-18%
Net profit
DKK 244K
-37%
Total assets
DKK 2,2M
+9%
Equity
DKK 1,7M
+7%
Employees
1
—
Company information
Legal name
BIOPHARM FORWARD ApS
CVR number
32438784
Legal form
Anpartsselskab
NACE code
7499 · All other professional, scientific and technical activities n.e.c.
Founded
26. august 2009
Share capital
DKK 131.250
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-08-25
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at drive konsulentvirksomhed indenfor life science området samt udøve aktiviteter i tilknytning hertil.
Contact
Address
Gammel Strandvej 442A, st. th
Email
johi@biopharmforward.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in All other professional, scientific and technical activities n.e.c.
Companies in Helsingør
All Denmark companies
Revenue
DKK millions
0M
0M
1M
1M
1M
1M
2021
1M
2022
1M
2023
1M
2024
1M
2025
EBITDA
DKK millions
0M
0M
1M
1M
1M
1M
2021
0M
2022
0M
2023
0M
2024
0M
2025
Income statement
DKK thousands
Item
2021
2022
2023
2024
2025
Revenue
928
584
550
1.057
997
Staff expenses
-254
-306
-679
-725
-725
EBITDA
674
278
-130
331
272
Depreciation & amort.
-0
-0
-0
-0
-0
EBIT
674
278
-130
331
272
Net financials
1.066
-78
-8
162
41
Profit before tax
1.740
200
-137
494
312
Tax
283
44
-30
108
69
Net profit
1.457
156
-107
385
244
Balance sheet
DKK thousands
Item
2021
2022
2023
2024
2025
Total assets
1.788
1.829
1.702
2.058
2.245
Equity
1.553
1.595
1.370
1.633
1.741
Long-term debt
0
0
0
78
69
Short-term debt
235
234
332
347
435
Total debt
235
234
332
425
503
Financial ratios
5-year trend
EBITDA margin
27.3%
This company
15.8%
Market median
+73% vs market
2021
2025
Equity ratio
77.6%
This company
38.2%
Market median
+103% vs market
2021
2025
Return on equity
14.0%
This company
18.4%
Market median
+24% vs market
2021
2025
Net profit margin
24.4%
This company
8.1%
Market median
+201% vs market
2021
2025
Asset turnover
0.44×
This company
1.12×
Market median
-61% vs market
2021
2025
Debt / equity
0.29×
This company
0.62×
Market median
+53% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via CVR / Virk · Period 2024-08-26 – 2025-08-25
View
PDF
Annual report 2024
Filed via CVR / Virk · Period 2023-08-26 – 2024-08-25
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2022-08-26 – 2023-08-25
View
PDF
Annual report 2022
Filed via CVR / Virk · Period 2021-08-26 – 2022-08-25
View
PDF
Annual report 2021
Filed via CVR / Virk · Period 2020-08-26 – 2021-08-25
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Former (1)
BE
Bodil Elisabeth Fransiska Ørkild
Management
Management
2012 – 2019
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Jonas Hink
Individual
100%
100%
2014
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of BIOPHARM FORWARD ApS also hold positions in
0
other companies.
Person
Role here
Other companies
Bodil Elisabeth Fransiska Ørkild
Management
0 companies